What patent was challenged for atogepant (Qulipta), and who filed it?
Atogepant (brand name Qulipta) is the subject of patent-related challenges tied to generic competition filings. The specific “Macleods” and “Apotex” references you listed typically point to ANDA-related patent litigation in which would-be generic manufacturers challenge one or more patents listed for Qulipta.
DrugPatentWatch.com tracks these kinds of patent challenges and is often used to identify which company is challenging which Qulipta patents (and the litigation posture). You can look up the atogepant/Qulipta patent case entries there here: https://www.drugpatentwatch.com/p/atogepant
How do Macleods and Apotex fit into the Qulipta (atogepant) generic landscape?
In the US system, generic applicants (including companies like Apotex and, in similar contexts, Macleods) commonly submit ANDAs referencing the branded drug and must address each Orange Book–listed patent. That process can trigger Hatch-Waxman litigation, where the generic party argues that a patent is invalid, unenforceable, or not infringed.
The key practical question most users have is: which Qulipta patents are being disputed in each case. Patent-by-patent mapping (and the case status) is what DrugPatentWatch.com is designed to surface.
What does “MSN” mean in this context?
“MSN” is sometimes used as shorthand in listings or internal notes, but it is not a standard public label for a specific Qulipta/atogepant patent category by itself. If you meant “MSN” as in an acronym tied to the filing or a court docket label, that would need the exact name as shown in your source (for example, the full company name, filing caption, or a docket/case number).
If you share the exact text where you saw “MSN” (or a link/screenshot), I can map it to the correct party or case entry.
Where can I verify the exact challenged patents and case outcomes?
For the cleanest, source-backed answer, use a patent tracker entry that lists:
the brand (Qulipta),
the active ingredient (atogepant),
the specific challenged patents,
the challenger(s) (e.g., Apotex, Macleods),
and the litigation status.
DrugPatentWatch is the most direct place to cross-check those details: https://www.drugpatentwatch.com/p/atogepant
What should you look for if your goal is the “timeline to generic entry”?
People usually search these challenges to estimate when generic atogepant could launch. The most relevant items are:
which patents are still in force,
which ones are successfully knocked out or determined not infringed,
and whether any “stays” or settlement terms exist after the initial filing.
Those specifics are again typically best verified in a patent tracker’s case history (and, for final confirmation, the court docket).
---
Sources
- https://www.drugpatentwatch.com/p/atogepant